Baseline Characteristics and Maintenance Therapy Choice on Symptom Control, Reliever ...
The study developed parametric drug–disease models using pooled clinical trial data to estimate patient-/disease-related factors and drug-specific properties, then explored how baseline characteristics influence treatment performance. Key findings include: higher baseline ACQ-5 scores linked to poorer asthma control and higher exacerbation risk; male non-smokers with BMI < 25 kg/m² and no recent exacerbations had lower risk compared to female smokers with BMI ≥ 25 kg/m² and prior exacerbations; smokers used more reliever medication; ACQ-5, BMI, and smoking status influenced immediate symptoms and exacerbation risk; FF/VI treatment showed lower exacerbation risk and higher reduction in reliever use compared to BUD/FOR; model-based approach distinguished patient-/disease-specific features from drug-specific properties; simulation scenarios indicated stepping up to FF/VI combination therapy could significantly reduce exacerbation risk; personalized management should consider factors like high BMI, low FEV1, exacerbation history, and female sex.
Reference News
The study developed parametric drug–disease models using pooled clinical trial data to estimate patient-/disease-related factors and drug-specific properties, then explored how baseline characteristics influence treatment performance. Key findings include: higher baseline ACQ-5 scores linked to poorer asthma control and higher exacerbation risk; male non-smokers with BMI < 25 kg/m² and no recent exacerbations had lower risk compared to female smokers with BMI ≥ 25 kg/m² and prior exacerbations; smokers used more reliever medication; ACQ-5, BMI, and smoking status influenced immediate symptoms and exacerbation risk; FF/VI treatment showed lower exacerbation risk and higher reduction in reliever use compared to BUD/FOR; model-based approach distinguished patient-/disease-specific features from drug-specific properties; simulation scenarios indicated stepping up to FF/VI combination therapy could significantly reduce exacerbation risk; personalized management should consider factors like high BMI, low FEV1, exacerbation history, and female sex.